A forced marriage of IL-2 and PD-1 antibody nurtures tumor-infiltrating T cells
Erin A. Holcomb, Weiping Zou
Abstract
IL-2 is a pleiotropic cytokine. In this issue of the JCI, Ren et al. report on the development of a low-affinity IL-2 paired with anti-PD-1 (PD-1-laIL-2) that reactivates intratumoral CD8+ T cells, but not CD4+ Treg cells. PD-1-laIL-2 treatment synergized with anti-PD-L1 therapy to overcome tumor resistance to immune checkpoint blockade (ICB) in tumor-bearing mice. Rejection of rechallenged tumors following PD-1-laIL-2 therapy demonstrated the establishment of a potent T cell memory response. Furthermore, PD-1-laIL-2 therapy manifested no obvious toxicity. These findings suggest the potential of PD-1-laIL-2 therapy in treating patients with cancer.
Topics & Concepts
BlockadeImmunologyAntibodyMedicineAntibody therapyCancer researchImmune systemT cellImmunotherapyBiologyNeoplasmCellTumor cellsImmune checkpointCell therapyAntibody responseDrug resistanceNegative therapeutic reactionCombination therapyCytotoxic T cellT lymphocyteClonal deletionVirologyCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy research